

SERIAL NO.: 08/966,940

FILED: NOVEMBER 10, 1997

SUPPLEMENTAL RESPONSE TO FINAL OFFICE ACTION

PAGE 3

- 1) admixing or binding a biologically-active factor selected from the group consisting of TNF- α and lymphotoxin and a target molecule with a colloidal metal to form a composition; and
- 2) administering the composition to the human or animal.

10.⁹ (Twice Amended) The method of Claim ⁸ 9, wherein the biologically-active factor is tumor necrosis factor ("TNF α ").

15.¹¹ (Thrice Amended) A method of treating a human or animal with a cancer or immune disease comprising administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition capable of targeting a particular tissue comprising a biologically-active factor selected from the group consisting of TNF- α and lymphotoxin and a target molecule admixed with or bound to a colloidal metal.

16.¹² (Twice Amended) The method of Claim ¹¹ 15, wherein the biologically-active factor is tumor necrosis factor ("TNF α ").

19.¹⁷ (Twice Amended) A method for the delivery of more than one biologically-active factor comprising administering to a human or animal a composition comprising more than one biologically-active factor selected from the group consisting of TNF- α and lymphotoxin and a target molecule admixed with or bound to a colloidal metal.

20.¹⁸ (Twice Amended) The method of Claim ¹⁷ 19 wherein the biologically active factor is tumor necrosis factor ("TNF α ").

21. (Twice Amended) A method for the targeted delivery of one or more biologically-active factors, comprising administering to a human or animal a composition comprising two or more biologically-active factors selected from the group consisting of TNF- α and lymphotoxin admixed with or bound to colloidal metal wherein at least one of the biologically-active factors is a target molecule

SERIAL NO.: 08/966,940

FILED: NOVEMBER 10, 1997

SUPPLEMENTAL RESPONSE TO FINAL OFFICE ACTION

PAGE 4

65 cont capable of binding a receptor on a cell membrane and wherein at least one of the biologically-active factors is released from the composition *in vivo*.

22. (Twice Amended) The method of Claim 21 wherein the biologically-active factor is tumor necrosis factor ("TNF α ").

24. (Twice Amended) A method of treating a human or animal with cancer or an immune disease comprising administering to the human or animal a composition comprising two or more biologically-active factor selected from the group consisting of TNF- α and lymphotoxin admixed with or bound to a colloidal metal, wherein at least one of the biologically-active factors is a target molecule capable of binding a receptor on a cell membrane.

25. (Twice Amended) The method of Claim 24 wherein the biologically-active factor is tumor necrosis factor ("TNF α ").

30. (Amended) The method of Claim 21, wherein the composition further comprises additional biologically-active factors admixed with or bound to the colloidal metal.

33.²⁰ (Amended) A method of treating a human or animal with a cancer comprising administering to the human or animal with the cancer a therapeutically effective amount of a composition comprising a biologically-active factor selected from the group consisting of TNF- α and lymphotoxin admixed with or bound to a colloidal metal.

34.²¹ (Amended) A method of treating a human or animal with a cancer or immune disease comprising administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition comprising a biologically-active factor which is tumor necrosis factor ("TNF α ") admixed with or bound to a colloidal metal.